BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, February 5, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

April 7, 2021

View Archived Issues

Bile acid sequestrant SAR-442357 improves experimental type 2 diabetes and comorbidities

Read More

C3aR is a potential therapeutic target in vascular cognitive impairment

Read More

Jacobio Pharmaceuticals and AbbVie initiate phase I/II study of JAB-3312

Read More

Enrollment commences in phase I study of recombinant IAP SYN-020

Read More

APX-3330 enters phase II development for diabetic retinopathy

Read More

FDA approves new expanded indication for Anavip

Read More

Zydus reports positive phase III data for PegiHep in patients with COVID-19

Read More

First patient dosed in a phase II study of ensovibep for the treatment of COVID-19

Read More

Antibodies could make things worse in neurodegeneration

Read More

Myeloid cells differ in primary and recurrent glioblastoma

Read More

Unnatural Products describes MDM2/4 bispecific inhibitor UNP-1797

Read More

U.S. researchers patent protein kinase inhibitors

Read More

Roche divulges new TLR antagonists

Read More

Cadila Healthcare presents new NLRP3 inflammasome inhibitors

Read More

Japanese investigators identify P2X4 receptor antagonists

Read More

Forevertek Biotechnology and ProMab Biotechnologies divulge MAbs against SLAM family member 7

Read More

Oryzon announces preclinical collaboration with Seaver Autism Center at Mount Sinai

Read More

Dosing begins in phase I study of the bispecific antibody TJ-L-14B/ABL-503

Read More

Pfizer's oral SARS-CoV-2 main protease inhibitor PF-07321332 enters phase I

Read More

Recognify Life Sciences initiates phase IIa trial of RL-007 in CIAS

Read More

An efficient target deconvolution approach based on highly parallelized CRISPR/Cas9 genome editing

Read More

MfpA protein acts a T-segment mimic to protect DNA gyrase from fluoroquinolones

Read More

Landos' IND for omilancor in eosinophilic esophagitis cleared in U.S.

Read More

Study shows neurological or psychiatric diagnoses for 1 in 3 COVID-19 survivors

Read More

Bridge Biotherapeutics begins phase I/II trial of BBT-176 in EGFR-mutant NSCLC with C797S

Read More

AzurRx starts phase II RESERVOIR study in patients with COVID-19 GI infection

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Feb. 5, 2025.
  • Art concept for medical research

    MicroRNAs in circulating extracellular vesicles as IPF biomarkers

    BioWorld Science
    MicroRNAs (miRNAs) are small noncoding RNAs gaining increasing attention due to their crucial role in gene expression regulation and influence in various cellular...
  • Brain illustration

    MJFF grant supports Bexorg’s translational biomarker work

    BioWorld Science
    Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
  • Brain and DNA

    REST emerges as biomarker in ALS, knockdown improves ALS symptoms

    BioWorld Science
    About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
  • Illustration of liver being targets with cross-hairs

    Study identifies CAND1 as therapeutic target in hepatoblastoma

    BioWorld Science
    Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing